Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ashton

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Biopharmaceutics & Drug Disposition|June 30, 2009
Artemisinin--a possible CYP2B6 probe substrate?Sara Asimus, Michael Ashton
Bioanalysis|January 9, 2026
A simple, sensitive and rapid bioanalytical method for quantifying cannabidiol (CBD), 7-OH-CBD and 7-COOH-CBD in human plasmaNattapon Jaisupa, Michael Ashton, Sofia Birgersson
Journal of Pharmaceutical Sciences|August 29, 2007
Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicityRasmus Jansson, Ulf Bredberg, Michael Ashton
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 2, 2025
Cannabidiol metabolism <i>in vitro</i>: the role of antiseizure medications and CYP2C19 genotypesNattapon Jaisupa, Michael Ashton, Sofia Birgersson
Cureus|August 17, 2022
Oral Metronidazole Desensitization for Immunoglobulin E (IgE)-Mediated HypersensitivityChantae C Hollis, Chamunorwa Mlauzi, Michael Ashton
Physical Review Letters|May 16, 2020
Ab initio Description of Bond Breaking in Large Electric FieldsMichael Ashton, Arpit Mishra, Jörg Neugebauer, et al.
Drug Metabolism Letters|March 20, 2013
The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomesTherese Ericsson, Collen Masimirembwa, Angela Abelo, et al.
The Journal of Antimicrobial Chemotherapy|August 2, 2021
Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIVJesper Sundell, Emile Bienvenu, Angela Äbelö, et al.
Antiviral Research|December 10, 2013
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patientsEmile Bienvenu, Marelize Swart, Collet Dandara, et al.
British Journal of Clinical Pharmacology|March 15, 2011
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotypeDinko Rekić, Daniel Röshammar, Jackson Mukonzo, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Biopharmaceutics & Drug Disposition|June 30, 2009
Artemisinin--a possible CYP2B6 probe substrate?Sara Asimus, Michael Ashton
Bioanalysis|January 9, 2026
A simple, sensitive and rapid bioanalytical method for quantifying cannabidiol (CBD), 7-OH-CBD and 7-COOH-CBD in human plasmaNattapon Jaisupa, Michael Ashton, Sofia Birgersson
Journal of Pharmaceutical Sciences|August 29, 2007
Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicityRasmus Jansson, Ulf Bredberg, Michael Ashton
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 2, 2025
Cannabidiol metabolism <i>in vitro</i>: the role of antiseizure medications and CYP2C19 genotypesNattapon Jaisupa, Michael Ashton, Sofia Birgersson
Cureus|August 17, 2022
Oral Metronidazole Desensitization for Immunoglobulin E (IgE)-Mediated HypersensitivityChantae C Hollis, Chamunorwa Mlauzi, Michael Ashton
Physical Review Letters|May 16, 2020
Ab initio Description of Bond Breaking in Large Electric FieldsMichael Ashton, Arpit Mishra, Jörg Neugebauer, et al.
Drug Metabolism Letters|March 20, 2013
The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomesTherese Ericsson, Collen Masimirembwa, Angela Abelo, et al.
The Journal of Antimicrobial Chemotherapy|August 2, 2021
Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIVJesper Sundell, Emile Bienvenu, Angela Äbelö, et al.
Antiviral Research|December 10, 2013
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patientsEmile Bienvenu, Marelize Swart, Collet Dandara, et al.
British Journal of Clinical Pharmacology|March 15, 2011
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotypeDinko Rekić, Daniel Röshammar, Jackson Mukonzo, et al.
Pageof 7